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Study protocol: Multi-parametric magnetic resonance imaging for therapeutic 
response prediction in rectal cancer 
Abstract 
Background 
Response to neoadjuvant chemoradiotherapy (CRT) of rectal cancer is variable. Accurate imaging for 
prediction and early assessment of response would enable appropriate stratification of management to 
reduce treatment morbidity and improve therapeutic outcomes. Use of either diffusion weighted imaging 
(DWI) or dynamic contrast enhanced (DCE) imaging alone currently lacks sufficient sensitivity and 
specificity for clinical use to guide individualized treatment in rectal cancer. Multi-parametric MRI and 
analysis combining DWI and DCE may have potential to improve the accuracy of therapeutic response 
prediction and assessment. 
Methods 
This protocol describes a prospective non-interventional single-arm clinical study. Patients with locally 
advanced rectal cancer undergoing preoperative CRT will prospectively undergo multi-parametric MRI pre-
CRT, week 3 CRT, and post-CRT. The protocol consists of DWI using a read-out segmented sequence 
(RESOLVE), and DCE with pre-contrast T1-weighted (VIBE) scans for T1 calculation, followed by 60 
phases at high temporal resolution (TWIST) after gadoversetamide injection. A 3-dimensional voxel-by-
voxel technique will be used to produce colour-coded ADC and Ktrans histograms, and data evaluated in 
combination using scatter plots. MRI parameters will be correlated with surgical histopathology. 
Histopathology analysis will be standardized, with chemoradiotherapy response defined according to 
AJCC 7th Edition Tumour Regression Grade (TRG) criteria. Good response will be defined as TRG 0–1, 
and poor response will be defined as TRG 2–3. 
Discussion 
The combination of DWI and DCE can provide information on physiological tumour factors such as 
cellularity and perfusion that may affect radiotherapy response. If validated, multi-parametric MRI 
combining DWI and DCE can be used to stratify management in rectal cancer patients. Accurate imaging 
prediction of patients with a complete response to CRT would enable a ‘watch and wait’ approach, 
avoiding surgical morbidity in these patients. Consistent and reliable quantitation from standardised 
protocols is essential in order to establish optimal thresholds of ADC and Ktrans and permit the role of 
multi-parametric MRI for early treatment prediction to be properly evaluated. 
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Abstract
Background: Response to neoadjuvant chemoradiotherapy (CRT) of rectal cancer is variable. Accurate imaging for
prediction and early assessment of response would enable appropriate stratification of management to reduce treatment
morbidity and improve therapeutic outcomes. Use of either diffusion weighted imaging (DWI) or dynamic
contrast enhanced (DCE) imaging alone currently lacks sufficient sensitivity and specificity for clinical use to
guide individualized treatment in rectal cancer. Multi-parametric MRI and analysis combining DWI and DCE may have
potential to improve the accuracy of therapeutic response prediction and assessment.
Methods: This protocol describes a prospective non-interventional single-arm clinical study. Patients with locally advanced
rectal cancer undergoing preoperative CRT will prospectively undergo multi-parametric MRI pre-CRT, week 3
CRT, and post-CRT. The protocol consists of DWI using a read-out segmented sequence (RESOLVE), and DCE
with pre-contrast T1-weighted (VIBE) scans for T1 calculation, followed by 60 phases at high temporal resolution (TWIST)
after gadoversetamide injection. A 3-dimensional voxel-by-voxel technique will be used to produce colour-coded ADC
and Ktrans histograms, and data evaluated in combination using scatter plots. MRI parameters will be correlated
with surgical histopathology. Histopathology analysis will be standardized, with chemoradiotherapy response defined
according to AJCC 7th Edition Tumour Regression Grade (TRG) criteria. Good response will be defined as TRG 0–1, and
poor response will be defined as TRG 2–3.
Discussion: The combination of DWI and DCE can provide information on physiological tumour factors such as cellularity
and perfusion that may affect radiotherapy response. If validated, multi-parametric MRI combining DWI and DCE can be
used to stratify management in rectal cancer patients. Accurate imaging prediction of patients with a complete response
to CRT would enable a ‘watch and wait’ approach, avoiding surgical morbidity in these patients. Consistent and reliable
quantitation from standardised protocols is essential in order to establish optimal thresholds of ADC and Ktrans and permit
the role of multi-parametric MRI for early treatment prediction to be properly evaluated.
Trial registration: Australian New Zealand Clinical Trials Registry (ANZCTR) number ACTRN12616001690448 (retrospectively
registered 8/12/2016).
Keywords: MRI, Rectal cancer, Radiotherapy, Response, Chemoradiotherapy, Diffusion weighted imaging, Dynamic contrast
enhanced, Diffusion, Perfusion
* Correspondence: Trang.Pham@health.nsw.gov.au
1Department of Radiation Oncology, Liverpool Cancer Therapy Centre,
Liverpool Hospital, South Western Sydney Local Health District, Sydney,
Australia
2Sydney West Radiation Oncology Network, Westmead, Blacktown and
Nepean Hospitals, Sydney, Australia
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Pham et al. BMC Cancer  (2017) 17:465 
DOI 10.1186/s12885-017-3449-4
Background
Locally advanced rectal cancer (LARC) requires multi-
modality treatment consisting of neoadjuvant chemora-
diotherapy (CRT) and standardized surgical technique
(total mesorectal excision) [1–3]. Response to neoadjuvant
therapy is variable; 15–27% of patients will have a patho-
logic complete response (pCR) [4], whilst 25–45% will have
a poor response with minimal tumour regression [5]. In
patients with locally advanced rectal cancer undergoing
CRT and surgery, 45% of patients will require permanent
colostomy [6]. Accurate imaging for prediction and early
assessment of response would enable appropriate stratifica-
tion of management to reduce treatment morbidity and
improve therapeutic outcomes. In patients with a clinical
complete response to CRT, substitution of surgery by a
‘watch-and-wait’ approach has emerged as a management
option [7–9]. Prediction of poor response could permit
trials of dose escalation strategies or curtailment of futile
treatment.
Functional magnetic resonance imaging (MRI) has
shown promising results for prediction of CRT response
in rectal cancer. Diffusion weighted imaging (DWI) has
demonstrated greater potential compared with morpho-
logic T2-weighted (T2-w) imaging for the assessment of
therapeutic response in rectal cancer patients [10]. How-
ever, a systematic review by Joye et al. found that pre-CRT
quantitative DWI alone was unable to predict pCR with
sensitivity and specificity of 69% and 68%, respectively.
Quantitative DWI post-CRT had sensitivity and specificity
of 78–80% and 72–78%, respectively, for detecting pCR
[11]. Some dynamic contrast enhanced (DCE) MRI stud-
ies have shown that higher contrast exchange rate pre-
treatment, as indicated by higher Ktrans, is associated with
better response to CRT [12, 13]. One study did not find a
correlation between pre-treatment Ktrans and therapeutic
response [14]. Use of either DWI or DCE alone currently
lacks sufficient accuracy for clinical use to guide individu-
alized treatment in rectal cancer.
Multi-parametric MRI combining DWI and DCE may
have potential to improve the accuracy of therapeutic re-
sponse prediction and assessment. Most published studies
describe mean values of a region of interest (ROI) from
either DWI or DCE. Single parameter measurements,
such as mean apparent diffusion co-efficient (ADC) or
Ktrans, do not adequately reflect intra-tumour heterogeneity.
A three-dimensional analysis of the tumour volume would
provide information on tumour heterogeneity. Development
and standardization of multi-parametric imaging protocols is
required to provide robust serial imaging datasets and reli-
able quantitative assessment of treatment response.
Study hypothesis
Multi-parametric MRI, consisting of DWI and DCE,
performed pre-, during- and post- neoadjuvant CRT is
predictive of treatment outcome in locally advanced rectal
cancer, with histopathology being the standard reference.
Methods/design
Study objectives
Primary objective
To prospectively evaluate pre-, during- and post-CRT
multi-parametric MRI (DWI and DCE) at 3 Tesla for
therapeutic response prediction in LARC. MRI bio-
markers will be correlated with histopathology tumour
regression grade (TRG).
Secondary objectives
1. To prospectively evaluate the role of DCE MRI for
therapeutic response prediction and assessment in
LARC.
2. To prospectively evaluate the role of DWI MRI
(RESOLVE) for therapeutic response prediction
and assessment in LARC.
3. To evaluate the different contributions of MRI and
PET for therapeutic prediction and assessment in
LARC.
4. To correlate MRI biomarkers with 2 year disease-free
survival and overall survival.
Study design
The study design is a prospective, single-arm, cohort
study to investigate the value of multi-parametric MRI
(combining DWI and DCE) in the prediction and assess-
ment of CRT response. Patients will receive standard treat-
ment for their malignancy. This study does not involve a
treatment intervention.
Study schematic
All patients will receive standard treatment consisting of
neoadjuvant CRT followed by surgery, and have MRI
and PET performed at three time-points (Fig. 1); pre-CRT,
during-CRT (week 3 of CRT), and post-CRT (within
1 week prior to surgery).
Patient selection
Inclusion criteria
1. Age greater than 18
2. Stage II or III rectal adenocarcinoma, defined as
T3 - T4 and/or node positive disease (N1–2),
without distant metastatic disease (M0)
3. No evidence of metastatic disease on computed
tomography (CT) chest/abdomen/pelvis
4. Undergoing treatment regimen consisting of
neoadjuvant CRT (Radiotherapy 50.4Gy in 28
fractions delivered using 3D–conformal or VMAT
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technique concurrent with infusional 5-fluorouracil
or oral capecitabine) followed by primary surgery.
Exclusion criteria
1. Other malignancy
2. Active inflammatory bowel disease
3. Contraindication to MRI:
○ Implanted ferromagnetic metal eg. Intraocular
metal
○ Pacemaker/Implantable defibrillator
○ Extreme claustrophobia
Treatment
Patients are to undergo standard treatment, consisting
of neo-adjuvant long course CRT (as detailed above)
followed by surgery, as recommended by treating team.
There will be no change to the patient’s treatment from
participating in this study.
Imaging study procedures
Timing of multi-parametric MRI and PET
1. Pre-CRT: week −2 to 0
2. During-CRT: Week 3 of CRT (early as possible
during week 3)
3. Post-CRT: Post completion of CRT, within 1 week
prior to surgery
MRI technique
All MRI scans will be acquired on the 3 Tesla Siemens
Skyra (Magnetom, Erlangen, Germany) dedicated MRI-
Simulator within the Radiation Oncology department.
A 32-channel spine coil integrated in the patient table
will be used in combination with an 18-channel phase
array surface coil strapped firmly around the pelvis.
Butylscopolamine (Buscopan) 20 mg will be administered
intravenously prior to acquisition of functional sequences
(DWI and DCE) to reduce rectal motion.
MRI safety screening
All patients will undergo MRI safety screening.
Screening of suitability for gadolinium-based MRI contrast
1. Require documentation of normal renal function
within three months (eGFR > = 60 ml/min/1.73 m2
2. Contra-indications to use of gadolinium-based MRI
contrast/DCE:
1. Renal impairment eGFR <60 ml/min/1.73 m2
2. Acute kidney injury
3. Previous allergic reaction to gadolinium-based
MRI contrast.
MRI sequences
T2-weighted turbo spin echo images - Acquired in 3
planes with 2 mm slice thickness and bandwidth
440 Hz/Px in 1 concatenation: (i) sagittal, (ii) axial ob-
lique, angulated perpendicular to the long tumour axis,
and (iii) axial. A T2-w HASTE sequence is additionally
acquired in the coronal plane.
Diffusion weighted imaging (DWI)
– Readout segmented diffusion technique (RESOLVE)
– Axial orthogonal plane with b-values 50 and
800 s/mm2, and 1 & 3 signal averages respectively.
– ADC maps and calculated b = 1400 mm/s2 images
produced as part of protocol.
– In-plane resolution of 1.1 × 1.1 mm and 4 mm slice
thickness.
Dynamic contrast enhanced (DCE) imaging
– Pre-contrast T1-weighted VIBE scans with TR
4.09 ms, TE 1.35 ms, and flip angles 2° and 15° to
calculate native T1.
– DCE acquired with time-resolved angiography with
stochastic trajectories (TWIST) technique acquired
over 60 phases, with a temporal resolution of 5.28 s,
bandwidth 440 Hz/Px, TR 3.67 ms and TE 1.48 ms.
Gadoversetamide (Optimark) 0.1 mM/kg injected
after 3 phases acquired.
Fig. 1 Study schematic
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PET/CT technique
18F–FDG PET/CT will be acquired on the GE Discovery-
710 PET-CT. Patients need to fast for at least 4 h prior to
4.29 ± 0.34 (mean ± SD) MBq/kg 18F -FDG injection and
have blood glucose levels <10 mmol/L. All PET scans will
be acquired in three-dimensional mode from the mid-brain
to proximal femora with an acquisition time of 1.5–2.5 min
per bed position, after an 18F–FDG uptake time of 60 min.
PET data will be reconstructed into a 256 × 256 matrix size
with slice thickness of 3.3 mm using GE VUE Point FX
(Time of Flight) algorithm. All PET/CT scans will be evalu-
ated on the Advantage Workstation (GE Healthcare) using
the AW VolumeShare 5 software and PET-VCAR (Volume
Computer-Assisted Reading) protocol.
Clinical assessment and acute toxicity grading
1. Radiation Oncology clinical assessments and formal
acute toxicity scoring will be performed at the
following time points:
a. Pre-CRT: Baseline assessment prior to
commencement of treatment
b. During-CRT: Weekly during radiotherapy treatment
reviews
c. Post-CRT: At 2 weeks post-completion of CRT,
and within 1 week prior to surgery (ideally at time
of post-CRT MRI).
2. Acute toxicity will be scored according to the
‘Common Terminology Criteria for Adverse Events
(CTCAE) Version 4.0.
Histopathology and tumour regression grade criteria
Histopathological assessment will be undertaken by a ded-
icated pathology team, with all reporting/TRG assessment
by pathologists with sub-specialisation in gastrointestinal
pathology. For the study it is a requirement that the whole
of the original tumour site should be embedded for micro-
scopic assessment.
MRI will be correlated with histopathological TRG
using the modified classification of Ryan et al. [15] set
out in the AJCC Cancer Staging Manual, 7th Edition as
follows:
TRG 0 (complete response) – no viable cancer cells.
TRG 1 (moderate response) – single cells or small groups
of cancer cells.
TRG 2 (minimal response) – residual cancer outgrown
by fibrosis.
TRG 3 (poor response) – minimal or no tumour kill;
extensive residual cancer.
Patients with TRG 0–1 will be categorized as ‘good
responders’ and those with TRG 2–3 categorized as
‘poor responders’ to CRT.
Multi-parametric imaging analysis
A Radiation Oncologist with sub-specialization in
gastrointestinal malignancies and a Radiologist with
sub-specialization in pelvic MRI will perform all seg-
mentations. Ktrans maps will be produced by first pre-
selecting an appropriate arterial input function, scaled
by dose, based on chi-squared goodness of fit, and
using a two-compartment Tofts model [16]. ADC and
Ktrans parameter maps will be exported in DICOM format
and registered to T2-w axial images.
The region of interest for analysis will be defined on the
entire hyper-intense primary tumour on the b-value
1400 mm/s s2 images. A voxel-by-voxel technique will be
used to produce colour-coded maps and histograms of ADC
and Ktrans, and combined scatterplots for each time-point.
Statistical considerations
A target of 35 patients will be recruited; this is estimated
to take 24 months. For estimated pCR rate of 25%, 35
patients will provide 80% power to detect an AUC ≥ 80%.
Poor responders rate is estimated to be in the range of
25–45% [5]. For estimated poor responder rate of 25%,
35 patients will provide 80% power to detect an AUC ≥ 80%.
For estimated poor responder rate of 45%, 35 patients will
provide 80% power to detect an AUC ≥ 76%.
Univariate analysis will be performed to investigate the
association between each MRI parameter and tumour
regression grade (AJCC 7th edition). Each MRI parameter
will be correlated with pathologic complete responders
(pCR - TRG 0) using a 2 × 2 Table. A similar analysis will
be performed for good responders (TRG0–1) vs. poor re-
sponders (TRG 2–3). Receiver operator characteristics
curves will be used to obtain an optimal threshold for
each MRI parameter (ADC and Ktrans).
Multivariate analysis will be performed to investigate the
association between multi-parametric MRI and tumour re-
gression grade. The multi-parametric MRI parameters that
will be used for multivariate analysis are ADC and Ktrans.
Discussion
MRI offers a variety of functional parameters, with each
parameter offering information on various biological
aspects of tumour. Multi-parametric image analysis has
become increasingly relevant in cancer therapy response
predication, as analysis of multiple parameters can provide
a more complete physiological assessment of tumour [17].
The rectum is a particularly challenging anatomy to image
and provide robust functional datasets that can be exam-
ined in a serial manner. In order to provide reliable quan-
titative assessment of treatment response, it is important
to have a standardized protocol that minimizes organ
motion and provides robust serial image datasets. This
study protocol describes standardized imaging procedures
combining DWI and DCE, and a 3D voxel-wise multi-
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parametric analysis strategy for the assessment of tumour
heterogeneity, and prediction of response to CRT in rectal
cancer. Both DWI and DCE techniques in this protocol
have improvements compared to previously used tech-
niques. The DWI RESOLVE sequence used in this study
protocol has previously been shown to be more robust with
respect to geometrical distortions, compared to DWI stand-
ard echo planar images [18]. The calculated b = 1400 mm/s2
images gains from both extra sensitivity and reduced noise
of a calculated high b-value. The short temporal resolution
of 5.28 s in DCE-TWIST will enable adequate sampling of
the rapid wash-in of contrast into tumour. For acquisition of
DCE images, the administration of butylscopolamine is
crucial in eliminating rectal motion and ensuring accurate
signal intensity for each pixel over the 60 time-points.
Figure 2 shows examples of the good quality functional
images with minimal distortion and corresponding par-
ameter maps that are able to be acquired with this
study protocol.
If validated, multi-parametric MRI combining DWI and
DCE can be used to stratify management in rectal cancer
patients. Accurate imaging prediction of patients with a
complete response to CRT would enable a ‘wait and watch’
approach, avoiding surgical morbidity in these patients.
Consistent and reliable quantitation from standardized pro-
tocols is essential in order to establish optimal thresholds of
ADC and Ktrans and permit the role of multi-parametric
MRI for early treatment prediction to be properly evaluated.
T2-weighted
DWI 
RESOLVE
calculated 
b=1400
ADC maps
K
trans
maps
Pre-CRT Week 3 CRT Post CRT
Fig. 2 MRI images and functional parameter maps produced as per study protocol. Images for a patient with good response to chemoradiotherapy (CRT)
with histopathology tumour regression grade 1 (AJCC 7th Edition). The rectal tumour is indicated by the arrow. In the T2-weighted week 3 image, it was
difficult to distinguish residual tumour deposits within areas of radiation-induced necrosis. Early tumour response to therapy can be seen in the functional
sequences. In the DWI-RESOLVE images, there was a reduction in tumour signal enhancement in week 3. The calculated b = 1400 mm/s2
images demonstrated increased signal intensity in tumour relative to surrounding normal tissues. Ktrans maps were produced in Siemens
Tissue 4D and a reduction in Ktrans was seen in week 3
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